MEDY-TOX INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 159,500 KRW | +4.32% |
|
+5.21% | -33.82% |
| May. 16 | Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 21 | Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,677,322 | 1,017,738 | 876,202 | 806,183 | 1,621,720 | 1,073,476 | - | - |
| Enterprise Value (EV) 2 | 1,758 | 1,109 | 914.6 | 903.4 | 1,669 | 1,165 | 1,181 | 1,073 |
| P/E ratio | 62.3 x | -32.8 x | 8.99 x | 22.3 x | 184 x | 35.7 x | 19.9 x | 12.4 x |
| Yield | 0.27% | 0.57% | - | - | 0.46% | 0.6% | 0.78% | 1.23% |
| Capitalization / Revenue | 8.15 x | 7.23 x | 4.74 x | 4.13 x | 7.33 x | 4.24 x | 3.55 x | 3.41 x |
| EV / Revenue | 8.54 x | 7.87 x | 4.95 x | 4.63 x | 7.55 x | 4.6 x | 3.91 x | 3.41 x |
| EV / EBITDA | 39.7 x | -58 x | 17.6 x | 14.6 x | 51.1 x | 24 x | 12.6 x | 8.72 x |
| EV / FCF | 139 x | -83.9 x | 373 x | 55.4 x | 285 x | 41.2 x | 24.7 x | 14.7 x |
| FCF Yield | 0.72% | -1.19% | 0.27% | 1.8% | 0.35% | 2.43% | 4.04% | 6.82% |
| Price to Book | 6.3 x | 4.02 x | 2.09 x | 1.8 x | 3.45 x | 2.17 x | 2.06 x | 1.72 x |
| Nbr of stocks (in thousands) | 6,453 | 6,412 | 6,393 | 6,298 | 6,729 | 6,730 | - | - |
| Reference price 3 | 259,929 | 158,730 | 137,048 | 128,000 | 241,000 | 159,500 | 159,500 | 159,500 |
| Announcement Date | 3/4/20 | 3/12/21 | 3/11/22 | 3/7/23 | 3/7/24 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 205.9 | 140.8 | 184.9 | 195.1 | 221.1 | 253.2 | 302.3 | 314.5 |
| EBITDA 1 | 44.27 | -19.12 | 51.87 | 61.98 | 32.7 | 48.48 | 93.72 | 123.1 |
| EBIT 1 | 25.69 | -37.07 | 34.49 | 46.66 | 17.32 | 36.89 | 80.57 | 112.4 |
| Operating Margin | 12.48% | -26.32% | 18.66% | 23.92% | 7.83% | 14.57% | 26.65% | 35.72% |
| Earnings before Tax (EBT) 1 | 25.15 | -42.14 | 129.4 | 49.31 | 15.74 | 35.95 | 77.52 | 114.1 |
| Net income 1 | 26.21 | -29.01 | 96.16 | 37.57 | 9.642 | 27.09 | 59.59 | 87.49 |
| Net margin | 12.73% | -20.6% | 52.01% | 19.26% | 4.36% | 10.7% | 19.71% | 27.82% |
| EPS 2 | 4,172 | -4,841 | 15,243 | 5,750 | 1,311 | 4,471 | 8,032 | 12,898 |
| Free Cash Flow 3 | 12,682 | -13,217 | 2,452 | 16,304 | 5,862 | 28,312 | 47,762 | 73,248 |
| FCF margin | 6,159.42% | -9,385.15% | 1,326.31% | 8,356.93% | 2,651.01% | 11,181.87% | 15,799.93% | 23,287.75% |
| FCF Conversion (EBITDA) | 28,644.56% | - | 4,727.04% | 26,307.35% | 17,927.61% | 58,403.97% | 50,962.06% | 59,479.06% |
| FCF Conversion (Net income) | 48,395.22% | - | 2,549.86% | 43,399.26% | 60,797.57% | 104,520.61% | 80,154.83% | 83,723.26% |
| Dividend per Share 2 | 691.1 | 907.0 | - | - | 1,100 | 964.7 | 1,237 | 1,968 |
| Announcement Date | 3/4/20 | 3/12/21 | 3/11/22 | 3/7/23 | 3/7/24 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 45.65 | 39.76 | 49.76 | 53.31 | 52.27 | 42.67 | 51.79 | 58.65 | 68 | 54.59 | 60.1 | 65.9 | 72.15 | 57 | 66.4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 0.5614 | - | 10.38 | 14.53 | 16.29 | 1.767 | 9.551 | 3.575 | 2.43 | -0.93 | 5.05 | 15.2 | 18.7 | 10.6 | 21.1 |
| Operating Margin | 1.23% | - | 20.85% | 27.25% | 31.17% | 4.14% | 18.44% | 6.1% | 3.57% | -1.7% | 8.4% | 23.07% | 25.92% | 18.6% | 31.78% |
| Earnings before Tax (EBT) 1 | -19.69 | - | 24.22 | 17.59 | 2.315 | - | 9.152 | 3.429 | -3.376 | -1.07 | 5.5 | 10.9 | 15.7 | 11.2 | 21.7 |
| Net income 1 | -107.4 | - | 19.23 | 13.21 | -0.57 | - | 8.979 | -2.323 | 12.08 | -1.47 | 3.85 | 11.15 | 13.05 | 8.6 | 16.7 |
| Net margin | -235.16% | - | 38.66% | 24.77% | -1.09% | - | 17.34% | -3.96% | 17.76% | -2.69% | 6.41% | 16.92% | 18.09% | 15.09% | 25.15% |
| EPS | - | 639.0 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/11/22 | 5/16/22 | 8/12/22 | 11/9/22 | 3/7/23 | 5/15/23 | 8/7/23 | 11/8/23 | 3/7/24 | 5/10/24 | - | - | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 80.6 | 91.2 | 38.4 | 97.2 | 47.7 | 91.7 | 108 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.821 x | -4.772 x | 0.7407 x | 1.568 x | 1.46 x | 1.891 x | 1.147 x | - |
| Free Cash Flow 2 | 12,682 | -13,217 | 2,452 | 16,304 | 5,862 | 28,312 | 47,762 | 73,248 |
| ROE (net income / shareholders' equity) | 10.2% | -11.4% | 29.7% | 8.96% | 2.12% | 5.65% | 12% | 15% |
| ROA (Net income/ Total Assets) | 6.42% | -6.52% | 18% | 6.31% | 1.62% | 3.54% | 9.61% | 12.3% |
| Assets 1 | 408.3 | 445.2 | 533.9 | 595.8 | 596.9 | 764.5 | 620.4 | 710.9 |
| Book Value Per Share 3 | 41,261 | 39,532 | 65,667 | 70,922 | 69,754 | 73,369 | 77,613 | 92,644 |
| Cash Flow per Share 3 | 5,366 | 4,570 | 3,266 | 4,191 | 2,019 | 8,836 | 10,925 | 13,147 |
| Capex 1 | 21 | 41.1 | 17.5 | 9.9 | 7.66 | 14.7 | 15 | 14.5 |
| Capex / Sales | 10.21% | 29.22% | 9.47% | 5.07% | 3.46% | 5.79% | 4.96% | 4.61% |
| Announcement Date | 3/4/20 | 3/12/21 | 3/11/22 | 3/7/23 | 3/7/24 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
159,500
KRW
Average target price
268,000
KRW
Spread / Average Target
+68.03%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.82% | 781M | |
| +6.96% | 101B | |
| +8.29% | 42.63B | |
| -11.09% | 33.5B | |
| +82.32% | 29.77B | |
| -11.82% | 16.14B | |
| +1.39% | 14.31B | |
| -12.13% | 11.55B | |
| +176.65% | 10.53B | |
| +6.74% | 9.2B |
- Stock Market
- Equities
- A086900 Stock
- Financials Medy-Tox Inc.
